Blood test to track prostate cancer in men on active surveillance
Tests a blood test for spotting worsening prostate cancer in men under surveillance.
Plain-language title generated from the registry record
Registry title: Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial)
Key facts
- Where
- Bern, SwitzerlandSee the site
Where in Switzerland
- Inselspital University Hospital of BernBern, SwitzerlandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Insel Gruppe AG, University Hospital Bern
- Trial code
- NCT07478536
- Record updated
- 22 June 2026
- Original description
The CHAS3 trial studies whether the Stockholm3 blood test can reliably detect if prostate cancer becomes more aggressive in men who are being carefully monitored instead of treated right away (active surveillance). The goal is to see if this test can help doctors safely follow patients with fewer invasive procedures, such as repeated biopsies.Read full original descriptionShow less
Multicenter Validation of the Stockholm3 Test on Men on Active Surveillance: the CHAS3-Trial
The CHAS3 trial studies whether the Stockholm3 blood test can reliably detect if prostate cancer becomes more aggressive in men who are being carefully monitored instead of treated right away (active surveillance). The goal is to see if this test can help doctors safely follow patients with fewer invasive procedures, such as repeated biopsies.
Inclusion: Adult Men ≥ 18 y. o; Men with low-risk prostate cancer (D'Amico risk classification) currently undergoing Active Surveillance (AS); First inclusion in Active Surveillance (AS) after 1st January 2022; Scheduled for follow-up with systematic and/or Magnetic Resonance Imaging (MRI)-targeted (fusion) prostate biopsies - Prostate Magnetic Resonance Imaging (MRI) performed within the past three months available.
Exclusion: - Prior prostate cancer treatment (surgery, radiation, chemotherapy, hormonal therapy); Patient with intermediate- or high-risk prostate cancer; Urinary catheterization within the past 6-8 weeks; Contraindications to Magnetic Resonance Imaging (MRI) or biopsy.